Plain-English translation of NCT07573176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depressive Disorder, Major research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help relieve depression symptoms more effectively than a placebo (a dummy pill with no active ingredient). The trial will run in two phases: first, a 6-week blinded phase where neither you nor the research team will know which treatment you're receiving, and then an optional longer phase where eligible participants can continue taking the medication openly for up to 6 months to check for long-term safety.
Major depressive disorder affects millions of people, and while some antidepressants work well, others don't help everyone. This trial explores whether this medication offers a new treatment option for people whose depression hasn't improved with current antidepressants or who couldn't tolerate them.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take a tablet once daily for 6 weeks during the double-blind phase—either the new medication or a placebo—without knowing which one. During this time, you'll have medical checkups, blood tests, and mood assessments to track how you're doing. If the medication appears safe and you're eligible, you can continue into an optional open-label phase lasting up to 6 months, where you'll know you're receiving the active medication and will continue to be monitored regularly.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States